ERBB2 and breast cancer: In particular, the pCR rate was higher in rapidly growing tumors, including triple-negative BC (EFS: HR 0.24, 95% CI 0.18–0.33; OS: HR 0.16, 95% CI 0.11–0.25) and HER2-positive BC (EFS: HR 0.39, 95% CI 0.31–0.50; OS: HR 0.34, 95% CI 0.24–0.47).